Specimens included in this study.

*<p> = these included three mothers in investigations of possible congenital transmission and four organ donors with chronic Chagas disease. PCR-testing was performed on these chronically infected persons to aid in the evaluation of disease transmission risk.</p

Effect of storage of EDTA blood specimens on real-time PCR results.

<p>The lower the Cq (quantitative cycle) value, the better recovery was obtained from the DNA extraction process.</p

Validation data for the real-time PCR assays.

<p>Validation data for the real-time PCR assays.</p

Detailed PCR findings from patients with reactivation disease.

<p>All of the patients in <a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0001689#pntd-0001689-t003" target="_blank">Table 3</a> tested positive in serology for Chagas disease and no decrease in antibody titer was detected during the monitoring period.</p><p>BC = buffy coat; only the buffy coat fraction was PCR positive for these samples.</p>†<p>indicate specimens that were collected during drug treatment (benznidazole or nifurtimox). Drug treatment information is missing for patients #4 and #9.</p

Specimens included in this study.

*<p> = these included three mothers in investigations of possible congenital transmission and four organ donors with chronic Chagas disease. PCR-testing was performed on these chronically infected persons to aid in the evaluation of disease transmission risk.</p

Detailed PCR-findings for recipients of organs from donors with suspected/confirmed chronic Chagas disease.

<p>All of the patients in <a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0001689#pntd-0001689-t004" target="_blank">Table 4</a> were serologically negative at time of transplant and none sero-converted during the time they were monitored at CDC.</p><p>BC = buffy coat; only the buffy coat fraction was PCR positive for these samples.</p>†<p>indicate specimens that were collected during drug treatment (benznidazole or nifurtimox). Drug treatment information is missing for patients #4 and #9.</p

Detailed PCR findings for patients with acute Chagas disease.

1<p>Patient was serologically positive for Chagas disease by the time she was tested at CDC.</p>2<p>Patient was serologically positive when 19 days old due to maternal antibodies. Another sample collected at 10 months of age tested negative in serology.</p>†<p>indicate specimens that were collected during drug treatment (benznidazole or nifurtimox).</p

Incident histoplasmosis cases (n) and proportion of early deaths (%) observed in the three main hospitals of French Guiana between 01/01/1992 and 09/30/2011.

<p>Incident histoplasmosis cases (n) and proportion of early deaths (%) observed in the three main hospitals of French Guiana between 01/01/1992 and 09/30/2011.</p

Description of baseline HIV infection and histoplasmosis infection characteristics and treatments in patients with AIDS-related histoplasmosis incident cases early death, in French Guiana, between 01/01/1992 and 09/30/2011.

<p>* One CD4 count missing value during the 1992–1997 period.</p>†<p>Good practices for fungal culture and serology were implemented in 1997–1998 and RT-PCR (Polymerase Chain Reaction using a Real-Time detection method) was implemented in 2006 in Cayenne General Hospital.</p>‡<p>3 patients received amphotericin B (liposomal or deoxycholate) and itraconazole or fluconazole simultaneously.</p><p>SD: Standard Deviation, IQR 25–75%: Interquartile range 25%–75%, HIV: Human Immunodeficiency Virus, HAART: Highly Active Antiretroviral Therapy, MGG: May Grünwald Giemsa, IV: Intravenously.</p

Number of deaths and early deaths observed among annual incident histoplasmosis cases diagnosed in the three main hospitals of French Guiana between 01/01/1992 and 09/30/2011.

<p>Number of deaths and early deaths observed among annual incident histoplasmosis cases diagnosed in the three main hospitals of French Guiana between 01/01/1992 and 09/30/2011.</p